AI reshaping biopharma manufacturing for faster drug development
Artificial intelligence (AI) is revolutionizing biopharma manufacturing by speeding up drug development and reshaping production facilities. AI-powered platforms can identify promising drug candidates and analyze vast biological datasets, significantly reducing the time required for early-stage development. In August 2026, Moderna and Merck announced positive late-stage trial results for a personalized mRNA cancer vaccine, showcasing the potential of AI-driven advancements.
The impact of AI extends to the design and construction of biopharma facilities. Companies like Eli Lilly, Merck, AstraZeneca, Novo Nordisk, Genentech, and Regeneron are investing heavily in U.S. manufacturing capacity. According to Andrew Ahrendt, director of national manufacturing at PCL Construction, three key trends are driving this transformation: speed, flexibility, and digital integration.
Speed is becoming the new normal, with AI compressing the capital planning cycle. Manufacturers now need to make facility decisions while drugs are still in evaluation, leading to increased interest in modular construction and collaborative delivery models. Flexibility is also crucial, as facilities must adapt to changing production needs. Many companies are opting for modular designs and expansion-ready utility infrastructure to accommodate multiple production strategies.
Digital integration is another critical factor. AI-driven tools like digital twins, predictive analytics, and real-time data collection are becoming essential for optimizing processes and monitoring equipment. PCL Construction is already incorporating digital twin-enabled documentation into project commissioning and closeout processes. Ahrendt emphasizes that digital-native strategies are now a necessity, not a luxury.
To keep pace with innovation, pharmaceutical manufacturers must ensure that facility development aligns with the rapid advancements in AI. Ahrendt notes that while AI compresses the science timeline, the physical realities of construction and commissioning do not compress at the same rate. Successful organizations will be those that build flexibility and coordination into projects from the beginning.